NEW YORK, Dec. 8, 2017 /PRNewswire/ -- In keeping with the commitment to dynamically provide members with timely information, WallStEquities.com has issued free tailored Stock Review on PZRX, ABEO, IMMY, and JAGX which is a click away at www.wallstequities.com/registration. On Thursday, the NASDAQ Composite ended the day at 6,812.84, up 0.54%; the Dow Jones Industrial Average edged 0.29% higher, to finish at 24,211.48; and the S&P 500 closed at 2,636.98, marginally gaining 0.29%. Gains were broad based as eight out of nine sectors finished the trading session in green. WallStEquities.com has initiated research reports on the following Biotechnology stocks: PhaseRx Inc. (NASDAQ: PZRX), Abeona Therapeutics Inc. (NASDAQ: ABEO), Imprimis Pharmaceuticals Inc. (NASDAQ: IMMY), and Jaguar Health Inc. (NASDAQ: JAGX). Following registration on Wall St. Equities, get access to today's free stock reports at:
www.wallstequities.com/registration
PhaseRx
Seattle, Washington headquartered PhaseRx Inc.'s stock finished Thursday's session 1.26% lower at $0.99 with a total trading volume of 442,172 shares. The stock has gained 45.21% in the past month and 76.32% over the past three months. The Company's shares are trading above their 50-day moving average by 20.17%. Moreover, shares of PhaseRx, which engages in developing a portfolio of products for the treatment of inherited enzyme deficiencies in the liver using intracellular enzyme replacement therapy, have a Relative Strength Index (RSI) of 58.21. Start your free membership with our free report on PZRX at:
www.wallstequities.com/registration/?symbol=PZRX
Abeona Therapeutics
Shares in Dallas, Texas-based Abeona Therapeutics Inc. rose 6.76%, ending yesterday's session at $15.80 with a total trading volume of 707,031 shares. The stock has gained 10.30% in the past month, 14.08% in the previous three months, 165.55% over the past twelve months, and 225.77% on an YTD basis. The Company's shares are trading above their 200-day moving average by 62.22%. Moreover, shares of Abeona Therapeutics, which focuses on developing and delivering gene therapy and plasma-based products for severe and life-threatening rare diseases, have an RSI of 46.24.
On November 08th, 2017, research firm SunTrust initiated a 'Buy' rating on the Company's stock, with a target price of $26 per share. Gain free access to the research report on ABEO at:
www.wallstequities.com/registration/?symbol=ABEO
Imprimis Pharmaceuticals
On Thursday, San Diego, California headquartered Imprimis Pharmaceuticals Inc.'s stock saw a decline of 2.26%, to close the day at $1.73. A total volume of 160,199 shares was traded. The Company's shares have advanced 6.79% in the last one month. The stock is trading above its 50-day moving average by 3.63%. Additionally, shares of Imprimis Pharma, which engages in the development, production, and sale of medications to physicians and patients in the US, have an RSI of 51.54. Register for your free report coverage on IMMY at:
www.wallstequities.com/registration/?symbol=IMMY
Jaguar Health
Shares in San Francisco, California-based Jaguar Health Inc. ended the day 4.21% higher at $0.13. A total volume of 1.72 million shares was traded. The Company's shares are trading below their 50-day moving average by 34.54%. Furthermore, shares of Jaguar Health, which focuses on developing and commercializing novel gastrointestinal prescription products from plants, have an RSI of 28.13. Get the free research report on JAGX at:
www.wallstequities.com/registration/?symbol=JAGX
--
Wall St. Equities:
Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
WSE has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
NO WARRANTY
WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
https://wallstequities.com/legal-disclaimer/
CONTACT
For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: [email protected] Phone number: +21-32-044-483Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
Advertisement
www.wallstequities.com/registration
PhaseRx
Seattle, Washington headquartered PhaseRx Inc.'s stock finished Thursday's session 1.26% lower at $0.99 with a total trading volume of 442,172 shares. The stock has gained 45.21% in the past month and 76.32% over the past three months. The Company's shares are trading above their 50-day moving average by 20.17%. Moreover, shares of PhaseRx, which engages in developing a portfolio of products for the treatment of inherited enzyme deficiencies in the liver using intracellular enzyme replacement therapy, have a Relative Strength Index (RSI) of 58.21. Start your free membership with our free report on PZRX at:
Advertisement
www.wallstequities.com/registration/?symbol=PZRX
Abeona Therapeutics
Shares in Dallas, Texas-based Abeona Therapeutics Inc. rose 6.76%, ending yesterday's session at $15.80 with a total trading volume of 707,031 shares. The stock has gained 10.30% in the past month, 14.08% in the previous three months, 165.55% over the past twelve months, and 225.77% on an YTD basis. The Company's shares are trading above their 200-day moving average by 62.22%. Moreover, shares of Abeona Therapeutics, which focuses on developing and delivering gene therapy and plasma-based products for severe and life-threatening rare diseases, have an RSI of 46.24.
On November 08th, 2017, research firm SunTrust initiated a 'Buy' rating on the Company's stock, with a target price of $26 per share. Gain free access to the research report on ABEO at:
www.wallstequities.com/registration/?symbol=ABEO
Imprimis Pharmaceuticals
On Thursday, San Diego, California headquartered Imprimis Pharmaceuticals Inc.'s stock saw a decline of 2.26%, to close the day at $1.73. A total volume of 160,199 shares was traded. The Company's shares have advanced 6.79% in the last one month. The stock is trading above its 50-day moving average by 3.63%. Additionally, shares of Imprimis Pharma, which engages in the development, production, and sale of medications to physicians and patients in the US, have an RSI of 51.54. Register for your free report coverage on IMMY at:
www.wallstequities.com/registration/?symbol=IMMY
Jaguar Health
Shares in San Francisco, California-based Jaguar Health Inc. ended the day 4.21% higher at $0.13. A total volume of 1.72 million shares was traded. The Company's shares are trading below their 50-day moving average by 34.54%. Furthermore, shares of Jaguar Health, which focuses on developing and commercializing novel gastrointestinal prescription products from plants, have an RSI of 28.13. Get the free research report on JAGX at:
www.wallstequities.com/registration/?symbol=JAGX
--
Wall St. Equities:
Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
WSE has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
NO WARRANTY
WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
https://wallstequities.com/legal-disclaimer/
CONTACT
For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: [email protected] Phone number: +21-32-044-483Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
View original content:http://www.prnewswire.com/news-releases/biotech-stocks-research-reports-released-on-phaserx-abeona-therapeutics-imprimis-pharma-and-jaguar-health-300568920.html
SOURCE Wall St. Equities
